News >

Expert Highlights RESPONSE Results With Ruxolitinib in Polycythemia Vera

Danielle Bucco
Published: Wednesday, Jan 10, 2018

Ruben Mesa, MD

Ruben Mesa, MD
Four-year follow-up data suggest that the majority of patients with polycythemia vera (PV) who responded to treatment with ruxolitinib (Jakafi) maintained those responses for up to 4 years, according to an analysis from the RESPONSE trial that was presented at the 2017 ASH Annual Meeting. Additionally, there were no new safety signals compared with the previous follow-up at 80 weeks.

during the 2017 ASH Annual Meeting, Mesa, director of the UT Health San Antonio Cancer Center, discussed the significance of the RESPONSE study for patients with PV.

OncLive: Please provide an overview of the RESPONSE trial.

Mesa: My colleagues and I presented the 4-year follow-up data from the RESPONSE study. The RESPONSE study investigated ruxolitinib as a second-line therapy for patients with PV. We demonstrated that, at 4-years of follow-up, the majority of patients remain on the therapy.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication